Commentary|Videos|February 1, 2024

Challenges With Addressing Neurodegeneration in Poststroke Patients: Stephen From

Author(s)Stephen From

The chief executive officer of Aruna Bio discussed the reasons for the failure of neuroprotective agents in ischemic stroke trials and why AB126 has potential to restore neurodegeneration in such affected patients. [WATCH TIME: 3 minutes]

WATCH TIME: 3 minutes

"If you’re going into that very extreme environment with an acute injury, you’re going to have to modulate the immune system and the inflammatory response. I believe that, and I could be wrong, but our product does all that. We didn’t design it; this is millions of years of evolution designed into our product. Not us, we just know how to harness it."

In early January, the FDA cleared an investigational new drug application for Aruna Bio to test its exosome therapy AB126 in patients with acute ischemic stroke that’s expected to begin in the first half of 2024. The study, a traditional dose-ascending trial, will assess the efficacy and safety of the therapy in those who had a poor prognosis post thrombectomy. Patients in the study will receive 3 intravenous injection treatments of AB126 at low, medium, and high doses.

According to the company, the agent has an intuitive ability to cross the blood-brain barrier and modulate inflammasome in the central nervous system through means of anti-inflammatory and neuroprotective mechanisms. To date, there has been no approved treatment that can address the neurodegeneration aspects of stroke and the disability that follows. Rehabilitation after a stroke begins in the hospital, often within a day or 2 after the stroke; however, recovery can be inconsistent for some patients, lasting weeks, months, or even years.

In a recent interview with NeurologyLive^®, Stephen From, chief executive officer of Aruna Bio, provided context on the difficulties with addressing neurodegeneration in poststroke patients and why previous trials have fallen short. He spoke on the mechanism of action of AB126 and why it may offer a more therapeutic benefit, especially in combination with other therapies.

REFERENCE
1. Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication. News Release. Aruna Bio. Published January 16, 2024. Accessed January 31, 2024. https://www.globenewswire.com/en/news-release/2024/01/16/2809846/0/en/Aruna-Bio-Announces-FDA-Clearance-of-IND-for-Lead-Program-AB126-Enabling-the-First-Exosome-to-Enter-in-Human-Clinical-Trials-for-a-Neurological-Indication.html

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Articles

MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
September 13th 2025
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
September 13th 2025
NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD
September 12th 2025
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
September 12th 2025
Expanding the Alzheimer Drug Development Pipeline
September 12th 2025

Latest CME

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

Samuel A. Frank, MD

Carolina Neuromuscular Disease Summit

In-Person + Virtual Event

Carolina Neuromuscular Disease Summit

September 27, 2025

SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials

Case-based Simulation

SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials

Jeff Gudin, MD

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

Daniel Claassen, MD, MS; Martha A. Nance, MD

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Alireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science into their Treatment Strategies

In-Person + Virtual Event

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science into their Treatment Strategies

October 9, 2025

4th Women in Neurology Conference

In-Person Event

4th Women in Neurology Conference

October 24-26, 2025

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

James F. Howard Jr, MD; Nicholas J. Silvestri, MD, FAAN; Neelam Goyal, MD

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Carrie M. Hersh, DO, MSc, FAAN; Anna Shah, MD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Alireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

October 31, 2025

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Paul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MD

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Trending on NeurologyLive

Expanding the Alzheimer Drug Development Pipeline

MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point

NeurologyLive® Friday 5 — September 12, 2025

FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency

© 2025 MJH Life Sciences^®

All rights reserved.